Glory trial: a new combo for large B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (glofitamab, gemcitabine, oxaliplatin) followed by liso-cel (a CAR T-cell therapy) for people with large B-cell lymphoma who have only had one prior treatment and whose lymphoma came back. The goal is to see if this approach works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of large B-cell lymphoma (like DLBCL) that has come back or not responded after just one prior treatment.
- You must be a candidate for a treatment called liso-cel (a CAR T-cell therapy).
- You must not have received CAR T-cells or a bispecific antibody before.
- Your kidneys, liver, and blood counts must be in a healthy enough range (your doctor will check).
- You cannot have any active serious infections or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.